Back to Search
Start Over
mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron.
- Source :
-
Cell reports [Cell Rep] 2022 Apr 12; Vol. 39 (2), pp. 110680. Date of Electronic Publication: 2022 Mar 25. - Publication Year :
- 2022
-
Abstract
- Knowledge about the impact of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the elderly on mRNA vaccination response is needed to appropriately address the demand for additional vaccinations in this vulnerable population. Here, we show that octogenarians, a high-risk population, mount a sustained SARS-CoV-2 spike-specific immunoglobulin G (IgG) antibody response for 15 months following infection. This response boosts antibody levels 35-fold upon receiving a single dose of BNT162b2 mRNA vaccine 15 months after recovery from coronavirus disease 2019 (COVID-19). In contrast, antibody responses in naive individuals boost only 6-fold after a second vaccine. Spike-specific angiotensin-converting enzyme 2 (ACE2) antibody binding responses in the previously infected octogenarians following two vaccine doses exceed those found in a naive cohort after two doses. RNA sequencing (RNA-seq) demonstrates activation of interferon-induced genetic programs, which persist only in the previously infected. A preferential increase of specific immunoglobulin G heavy chain variable (IGHV) clonal transcripts that are the basis of neutralizing antibodies is observed only in the previously infected nuns.<br />Competing Interests: Declaration of interests The authors declare no competing interests.<br /> (Published by Elsevier Inc.)
- Subjects :
- Aged
Aged, 80 and over
Antibodies, Neutralizing immunology
Antibodies, Viral immunology
BNT162 Vaccine
Humans
Immunoglobulin G
Octogenarians
RNA, Messenger genetics
Spike Glycoprotein, Coronavirus
Vaccination
Vaccines, Synthetic
Antibody Formation immunology
COVID-19 immunology
COVID-19 prevention & control
COVID-19 virology
SARS-CoV-2 immunology
mRNA Vaccines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2211-1247
- Volume :
- 39
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Cell reports
- Publication Type :
- Academic Journal
- Accession number :
- 35395191
- Full Text :
- https://doi.org/10.1016/j.celrep.2022.110680